Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• KRAS mutations, particularly in exon 2 (c.34G > T, p.G12C), are the most frequent alterations in non-small cell lung cancer (NSCLC), affecting about 30% of Caucasian patients.
• KRAS mutations have emerged as critical factors in NSCLC management, influencing patient prognosis and therapeutic strategies.

Purpose of the Study:

• To review the clinical significance of KRAS mutations in NSCLC.
• To discuss the efficacy of emerging KRAS inhibitors, such as Sotorasib and Adagrasib, targeting the KRAS-G12C variant.
• To explore mechanisms of resistance to KRAS inhibitors and their interaction with immune checkpoint inhibitors.

Main Methods:

• Literature review focusing on clinical aspects of KRAS mutations in NSCLC.
• Analysis of emerging efficacy data for Sotorasib and other KRAS inhibitors.
• Discussion of resistance mechanisms and immunotherapy interactions.

Main Results:

• KRAS-mutant lung adenocarcinoma (AC) patients often exhibit poorer overall survival (OS).
• KRAS inhibitors Sotorasib (FDA/EMA approved) and Adagrasib (FDA review) specifically target the KRAS-G12C mutation.
• Emerging data suggest potential efficacy of these targeted therapies, with ongoing investigations into resistance and combination strategies.

Conclusions:

• KRAS mutations play a dual role in NSCLC: they are prognostic markers and therapeutic targets.
• Targeted inhibition of KRAS-G12C represents a significant advancement in NSCLC treatment.
• Further research is needed to overcome resistance and optimize combination therapies, including with immune checkpoint inhibitors.